keyword
MENU ▼
Read by QxMD icon Read
search

Oral immunotherapy

keyword
https://www.readbyqxmd.com/read/29455358/the-use-of-biomarkers-to-predict-aero-allergen-and-food-immunotherapy-responses
#1
REVIEW
Sayantani B Sindher, Andrew Long, Swati Acharya, Vanitha Sampath, Kari C Nadeau
The incidence of allergic conditions has continued to rise over the past several decades, with a growing body of research dedicated toward the treatment of such conditions. By driving a complex range of changes in the underlying immune response, immunotherapy is the only therapy that modulates the immune system with long-term effects and is presently utilized for the treatment of several atopic conditions. Recent efforts have focused on identifying biomarkers associated with these changes that may be of use in predicting patients with the highest likelihood of positive clinical outcomes during allergen immunotherapy (AIT), providing guidance regarding AIT discontinuation, and predicting symptomatic relapse and the need for booster AIT after therapy...
February 17, 2018: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/29453437/enhancement-of-immunomodulative-effect-of-lactic-acid-bacteria-on-plasmacytoid-dendritic-cells-with-sucrose-palmitate
#2
Masaya Kanayama, Yukiko Kato, Toshikazu Tsuji, Yuki Konoeda, Akiko Hashimoto, Osamu Kanauchi, Toshio Fujii, Daisuke Fujiwara
Plasmacytoid dendritic cells (pDCs) play a key role in the immune response against viruses. In addition, recent research has suggested that pDCs possess direct and indirect tumoricidal activities. We previously found that a lactic acid bacteria strain, Lactococcus lactis JCM 5805 (LC-Plasma), stimulated pDCs and prevented viral infection in mouse and human studies. Meanwhile, emulsifiers have recently been highlighted as candidate adjuvants for some viral vaccines and cancer immunotherapies. In this study, we discovered some specific emulsifiers, mainly consisting of sucrose fatty acid esters, that drastically enhance the potency of LC-Plasma to activate pDCs in vitro...
February 16, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29452669/optimal-management-of-the-young-patient-cll-patient
#3
REVIEW
John N Allan, Richard R Furman
The emergence of targeted therapy for patients with chronic lymphocytic leukemia (CLL) has permanently altered the therapeutic landscape. In both upfront and relapsed settings, safe and effective oral kinase inhibitors are available which rival the responses and durability seen with standard chemo immunotherapy regimens. In 2016, ibrutinib was granted Federal Drug Administration approval for first-line therapy in patients with CLL. While its role as initial therapy for older, unfit or deleted 17p CLL patients is less controversial, its role as first-line treatment for younger fit patients is less clear, begging the question, what is the optimal treatment for these patients, novel agents or standard CIT strategies? In this review, we aim to provide guidance for what we believe is the optimal management of young fit patients with CLL...
March 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29447002/recent-treatment-modalities-for-cardiovascular-diseases-with-a-focus-on-stem-cells-aptamers-exosomes-and-nanomedicine
#4
Rahul Mittal, Vasanti M Jhaveri, Hannah S McMurry, Sae-In Samantha Kay, Kyle J Sutherland, Lin Nicole, Jeenu Mittal, Rahul Dev Jayant
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Due to the significant impact of CVD on humans, there is a need to develop novel treatment modalities tailored to major classes of cardiac diseases including hypertension, coronary artery disease, cardiomyopathies, arrhythmias, valvular disease and inflammatory diseases. In this article, we discuss recent advancements regarding development of therapeutic strategies based on stem cells, aptamers, exosomes, drug-eluting and dissolvable stents, immunotherapy and nanomedicine for the treatment of CVD...
February 15, 2018: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/29433557/metastatic-uveal-melanoma-showing-durable-response-to-anti-ctla-4-and-anti-pd-1-combination-therapy-after-experiencing-progression-on-anti-pd-1-therapy-alone
#5
Muhammad Zubair Afzal, Rodwell Mabaera, Keisuke Shirai
BACKGROUND: Uveal melanoma accounts for 85% of the ocular melanomas and has an increased risk of hematogenous spread, most commonly to the liver. After curative intent therapy like surgery and radiation, fifty percent of patients present with distant metastasis. Metastatic uveal melanoma (MUM) does not harbor typically targetable mutations, e.g., BRAF as in cutaneous melanoma. As a result, there is no proven therapy for MUM. Various chemotherapy and immunotherapy regimens have been tried and only partial response (PR) is the best that has been achieved in most of the cases...
February 12, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29432959/impact-of-adverse-event-solicitation-on-the-safety-profile-of-sq-house-dust-mite-sublingual-immunotherapy-tablet
#6
Hendrik Nolte, David I Bernstein, Gordon L Sussman, Bodil Svanholm Fogh, Susan Lu, Bernt Husøy, Harold S Nelson
BACKGROUND: It has been recommended that sublingual immunotherapy (SLIT) safety be assessed using solicited adverse event (AE) collection methods. OBJECTIVES: To describe the impact on the safety profile of SQ house dust mite (HDM) SLIT-tablet (12 SQ-HDM dose) when pre-specified local application site reactions were solicited vs unsolicited, and discuss ramifications of AE solicitation. METHODS: Subjects were randomized to daily 12 SQ-HDM or placebo for up to 52 weeks in 4 double-blinded, multicenter trials...
February 9, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29428795/poly-anhydride-nanoparticles-containing-cashew-nut-proteins-can-induce-a-strong-th1-and-treg-immune-response-after-oral-administration
#7
Marcela Araújo Pereira, Juliana de Souza Rebouças, Rafaela de Siqueira Ferraz Carvalho, Inés Luis de Redín, Priscila Valera Guerra, Carlos Gamazo, Claudia Ida Brodskyn, Juan M Irache, Nereide Stela Santos-Magalhães
Cashew nut allergy is the second most commonly reported tree nut allergy. Traditional allergen immunotherapy presents several clinical drawbacks that can be reduced by using nanoparticles-basedallergen-delivery systems, modulating the immune response towards a protective one. In this context, the goal of this work was to assess the potential of poly(anhydride) nanoparticles (NP) for cashew nut oral immunization. Cashew nut allergens-loaded nanoparticles (CNE-NP) were prepared by solvent displacement method...
February 8, 2018: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/29427729/liver-injury-from-cancer-immunotherapy-using-monoclonal-immune-checkpoint-inhibitors
#8
Eleonora De Martin, Jean-Marie Michot, Barbara Papouin, Stéphane Champiat, Christine Mateus, Olivier Lambotte, Bruno Roche, Teresa Maria Antonini, Audrey Coilly, Salim Laghouati, Caroline Robert, Aurélien Marabelle, Catherine Guettier, Didier Samuel
BACKGROUND & AIMS: Immunotherapy for metastatic cancer may be complicated by the onset of hepatic immune-related adverse events (IRAEs). This study compared hepatic IRAEs associated with anti-PD-1/PD-L1 and anti-CTLA-4 monoclonal antibodies (mAb). METHODS: Among 536 patients treated with anti-PD-1/PD-L1 or CTLA-4 immunotherapies, 19 (3.5%) were referred to the liver unit for grade ≥ 3 hepatitis. Among 16 included patients: 9 received anti-PD-1/PD-L1 while 7 received anti-CTLA-4 mAb, in monotherapy or in combination with anti-PD-1...
February 7, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29423374/the-international-study-of-the-allergic-rhinitis-survey-outcomes-from-4-geographical-regions
#9
Desiderio Passali, Cemal Cingi, Paola Staffa, Francesco Passali, Nuray Bayar Muluk, Maria Luisa Bellussi
Background: Allergic rhinitis (AR) is a global health problem and is characterised by one or more symptoms, including sneezing, itching, nasal congestion and rhinorrhea. Objective: We investigated the features of AR and the physician's approach to the management of AR patients in four geographical regions. Methods: In this cross-sectional study, a questionnaire survey concerning AR was completed by Honorary and Corresponding Members of the Italian Society of Rhinology from different countries among 4 world geographical regions-Asia, Europe, the Americas, and Africa...
January 2018: Asia Pacific Allergy
https://www.readbyqxmd.com/read/29423108/cancer-immunogenomic-approach-to-neoantigen-discovery-in-a-checkpoint-blockade-responsive-murine-model-of-oral-cavity-squamous-cell-carcinoma
#10
Paul Zolkind, Dariusz Przybylski, Nemanja Marjanovic, Lan Nguyen, Tianxiang Lin, Tanner Johanns, Anton Alexandrov, Liye Zhou, Clint T Allen, Alexander P Miceli, Robert D Schreiber, Maxim Artyomov, Gavin P Dunn, Ravindra Uppaluri
Head and neck squamous cell carcinomas (HNSCC) are an ideal immunotherapy target due to their high mutation burden and frequent infiltration with lymphocytes. Preclinical models to investigate targeted and combination therapies as well as defining biomarkers to guide treatment represent an important need in the field. Immunogenomics approaches have illuminated the role of mutation-derived tumor neoantigens as potential biomarkers of response to checkpoint blockade as well as representing therapeutic vaccines...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29422859/successful-subcutaneous-allergen-specific-immunotherapy-in-refractory-atopic-keratoconjunctivitis-a-case-report
#11
Passara Jongkhajornpong, Wannada Laisuan
Purpose: We report a case of refractory atopic keratoconjunctivitis (AKC) which was successfully treated with subcutaneous immunotherapy (SCIT). Case Report: A 22-year-old woman presented with severe allergic conjunctivitis for one and a half year. She failed to respond to conventional topical anti-allergic medications, topical corticosteroid, as well as topical cyclosporine A. Therefore, oral corticosteroids had to be prescribed to control the exacerbation for 1 year...
September 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/29413339/current-insights-in-allergen-immunotherapy
#12
REVIEW
Giovanni Passalacqua, Diego Bagnasco, Matteo Ferrando, Enrico Heffler, Francesca Puggioni, Giorgio Walter Canonica
OBJECTIVE: Allergen-specific immunotherapy (AIT) in its subcutaneous and sublingual forms is currently a well-established and experimentally supported treatment for respiratory allergy and hymenoptera venom allergy. There have been advances in its use linked strictly to the advancement in the knowledge of the molecular mechanisms of allergy, the production of well-characterized extracts, and diagnostic techniques. The use of AIT in asthma and the application of new approaches are expanding...
February 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29397272/eosinophilic-esophagitis-and-symptoms-possibly-related-to-eosinophilic-esophagitis-in-oral-immunotherapy
#13
Daniel Petroni, Jonathan M Spergel
No abstract text is available yet for this article.
January 31, 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29397193/the-poly-adp-ribose-polymerase-inhibitor-niraparib-management-of-toxicities
#14
Kathleen N Moore, Mansoor Raza Mirza, Ursula A Matulonis
Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is currently approved by the United States Food and Drug Administration (US FDA) as well as recently approved by the European Medicines Agency (EMA) for the maintenance treatment of women with recurrent ovarian cancer who are in complete or partial response to platinum-based chemotherapy. The mechanisms of action of niraparib include inhibition of PARP enzymatic activity as well as increased formation of PARP-DNA complexes through "trapping" the PARP enzyme on damaged DNA...
January 31, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29393170/predictors-of-persistent-milk-allergy-in-children-a-retrospective-cohort-study
#15
Yumi Koike, Sakura Sato, Noriyuki Yanagida, Tomoyuki Asaumi, Kiyotake Ogura, Kiyotaka Ohtani, Takanori Imai, Motohiro Ebisawa
BACKGROUND: Cow's milk (CM) allergy is the second most common food allergy developed during infancy in Japan. To identify predictors of persistent CM allergy, we investigated the tolerance acquisition rate based on an oral food challenge in children under 6 years of age, diagnosed with immediate-type CM allergy. METHODS: This retrospective cohort study included 131 children born in 2005 with a history of immediate allergic reaction to CM, of whom 39 were excluded because of ongoing oral immunotherapy (n = 18) or a lack of follow-up data (n = 21)...
January 23, 2018: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/29374499/long-term-efficacy-of-standardised-specific-subcutaneous-immunotherapy-in-children-with-persistent-allergic-rhinitis-due-to-multiple-allergens-including-house-dust-mites
#16
Y Song, J Long, T Wang, J Xie, M Wang, G Tan
OBJECTIVES: To observe the five-year efficacy of standardised specific subcutaneous immunotherapy for house dust mite allergy in monosensitised and polysensitised children with persistent allergic rhinitis. METHODS: From January 2007 to August 2009, 236 children with persistent allergic rhinitis were divided into 2 groups: 1 group received standardised specific subcutaneous immunotherapy using house dust mite extract; the other received pharmacotherapy with intranasal corticosteroids and oral antihistamines...
January 28, 2018: Journal of Laryngology and Otology
https://www.readbyqxmd.com/read/29369411/safety-and-efficacy-of-epicutaneous-immunotherapy-for-food-allergy
#17
REVIEW
Julie Wang, Hugh A Sampson
Food allergy is increasingly common in children, affecting about 4-8%. The mainstays of management remain allergen avoidance and emergency preparedness to treat allergic reactions with emergency medications. Unfortunately, these approaches are unsatisfactory for many patients and their families as the restrictions, constant vigilance and unpredictable severity of allergic reactions negatively impact quality of life. In recent decades, there has been significant interest in developing treatments for food allergy that lead to desensitization in order to increase thresholds for triggering allergic reactions and decrease the risk of reacting to allergen-contaminated food products...
January 25, 2018: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/29368051/role-of-immunotherapy-in-bladder-cancer-past-present-and-future
#18
REVIEW
Sabeeh-Ur-Rehman Butt, Laeeq Malik
As research focus in oncology has recently shifted from oral targeted therapy to immunomodulation, the era of successful drug development in bladder cancer has just begun. This has led to unprecedented approval of five immunotherapeutic agents by regulatory agencies for metastatic bladder cancer within a span of 12 months. With an initial triumph of anti-programmed cell death-1 (anti-PD-1) and anti-programmed cell death ligand-1 (anti-PDL-1) drugs, ongoing efforts are aimed at identification and validation of new druggable immune targets to consolidate the initial gains...
January 24, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29357949/the-150-most-important-questions-in-cancer-research-and-clinical-oncology-series-questions-86-93-edited-by-chinese-journal-of-cancer
#19
EDITORIAL
(no author information available yet)
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which spark diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 8 more questions are presented as follows. Question 86. In which circumstances is good supportive care associated with a survival advantage in patients with cancer? Question 87. Can we develop animal models to mimic immunotherapy response of cancer patients? Question 88...
January 22, 2018: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/29355619/nanotherapeutics-in-oral-and-parenteral-drug-delivery-key-learnings-and-future-outlooks-as-we-think-small
#20
REVIEW
Puneet Tyagi, J Anand Subramony
Nanotechnology ushered the field of medicine in to a new era. Miniaturization, increased surface area, and the unique physicochemical properties in the nano dimension were explored for new applications. Pharmaceutical industry picked up the technology and early success came fast for oral drug delivery through improvement in dissolution properties of the active molecules. Many products were launched using the nanocrystal technology on the oral side. Further development of polymeric nanoparticles led to wide spread research of nanocarriers for parenteral delivery...
January 16, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
keyword
keyword
54123
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"